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Метаболниот синдром (МС) е главен клинички и јавноздравствен предизвик во светот во 
пресрет на урбанизација, вишок на енергетски внес, зголемување на дебелината, седен-
тарен (седечки) начин на живот и навики. МС ќе предизвика за 5-пати зголемување на 
ризикот од дијабетес мелитус тип 2 (T2DM) и 2-пати зголемување на ризикот од кардио-
васкуларни болести (КВБ) во текот на следни 5 до 10 години. Цел на истражувањето е 
да се одреди преваленцата на метаболниот синдром  во регионот на Пеќ според крите-
риумите на NCEP ATD III / 2001. Материјал и методи: Студија на пресек (cross sectional 
study) е спроведена во Општата болница во Печ, која преставува регионална болница за 
Печкиот округ. Примерокот се состои од 1667 пациенти во период од една година. Резул-
тати: Кај анкетираните пациенти МС е застапен  кај 506 пациенти. Во најголем процент 
анкетираните го исполнуваат условот систолен крвен притисок ≥ 130 mmHg -99.4%, потоа 
следи дијастолен крвен притисок ≥ 85 mmH-96.4%, покачени триглицериди ≥ 1.7 mmol/L- 
94.7%, обемот на половината > 88см кај  жени-94.0%, покачена гликемија ≥ 6.1mmol/L кај 
80.0%, обем на половина >102см кај мажи-65.5%,  вредности на HDL <1.03mmol/L кај мажи 
56.9%,  вредности на HDL <1.03mmol/L кај жени  51.5%. Просечната вредност на систолниот 
крвен притисок кај пациентите со МС изнесува 151.1±9.3mmHg. Просечната вредност на 
дијастолниот  крвен притисок кај пациентите со МС изнесува 91.0±4.7mmHg. Просечниот 
обем на половината на анкетираните пациентите со МС изнесува 103.6±9.2см. Просечната 
вредност на HDL кај пациентите со МС изнесува 1.1±0.2 mmol/L. Просечната вредност на 
гликемија кај пациентите со МС изнесува 6.5±0.6 mmol/. Просечната вредност на тригли-
цериди  кај пациентите со МС изнесува 2.5±0.8 mmol/L. Најзастапена каj пациентите со 
МС е гојазност/обеситас – 70.8%, со прекумерна тежина  се 27.8%, и 1.4% се регистрираат 
нормална тежина. Заклучок: Преваленцијата на МС во Печкиот округ изнесува 30,4% и е 
приближно како во Хрватска 34%, и во Тетово со 28,25%, но зависи од популацијата и де-
финициите што се користат. Метаболниот синдром е една од главните јавноздравствени 
проблеми, социоекономски проблем во целиот свет, но и во Косово истотака.
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The metabolic syndrome (MS) is the main clinical and public health challenge in the world, in 
the wake of urbanization, excess energy intake, increased obesity, sedentary lifestyle and habits. 
MS leads to a 5-fold increase the risk of diabetes mellitus type 2 (T2DM) and 2 times the risk of 
cardiovascular disease (CVD) over the next 5 to 10 years. The aim of the research is to determine 
the prevalence of metabolic syndrome syndrome in the Pech District according to NCEP ATD III 
/ 2001. Material and methods: Cross sectional study was carried out at the General Hospital in 
Pec, which represents a regional hospital for the Pec District. A total of 1667 patients from the 
Pech district were interviewed for a period of one year. Results: In the group, MS was present in 
506 patients. In the majority of cases, we found the systolic blood pressure condition ≥ 130 mmHg 
-99.4%, followed by diastolic blood pressure ≥ 85 mmH-96.4%, elevated triglycerides ≥ 1.7 mmol / 
l- 94.7%, waist circumference> 88 cm in women-94.0% , increased glycemia ≥ 6.1mmol / L in 80.0%, 
waist circumference > 102cm in men-65.5%, HDL values <1.03mmol / L in men - 56.9%  and HDL 
values <1.03mmol / L in females 51.5%. The mean value of systolic blood pressure in patients 
with MS is 151.1 ± 9.3 mmHg. The average value of diastolic blood pressure in patients with MS is 
91.0 ± 4.7 mmHg. The average waist circumference of patients with MC was 103.6 ± 9.2 cm. The 
mean HDL of patients with MS is 1.1 ± 0.2 mmol / L. The average glycemic value in patients with 
MS is 6.5 ± 0.6 mmol / Average triglyceride value in patients with MS and is 2.5 ± 0.8 mmol / L. 
The most common in patients with MS is obesity / obesity - 70.8%, overweight is 27.8%, and 1.4% 
normal weight is registered. Conclusions: The prevalence of MS in the Pech district is 30.4% and 
was approximately as in Croatia 34% and Tetovo region with 28.25%, but it was dependent on 
the population and definitions used. The metabolic syndrome is one of the major public health 
problems, and a socioeconomic problem around the world and in  Kosovo, too.
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Introduction
Demographic changes combined with in-
creased prevalence of obesity and physical 
inactivity and urbanization are the most 
risk factors that explain the increase in the 
metabolic syndrome problem in a global 
perspective. This is a common knowledge 
for decades, but nevertheless, very few stud-
ies focus on actual changes in lifestyle-re-
lated factors1.  The metabolic syndrome 
(MS) is the main clinical and public health 
challenge in the world in time of urban-
ization, increased energy intake, increased 
obesity, sedentary lifestyle and habits. MS 
will increase the risk of diabetes mellitus 
type 2 (T2DM) five times and 2 times the 
risk of cardiovascular disease (CVD) over 
the next 5 to 10 years2.
In 1981, the term „metabolic syndrome“ was 
used to describe the common occurrence 
of hyperlipoproteinaemia, diabetes, hyper-
tension, gout, and obesity in combination 
with an increased incidence of cardiovas-
cular disease, fatty liver and cholelithiasis3. 
The metabolic syndrome (MS) is one set of 
risk factors, which predispose to the devel-
opment of type 2 diabetes (T2DM) and car-
diovascular disease (CVD)4.
Several definitions of the Metabolic Syn-
drome (6 of the number) are proposed. 
The first definition is defined by the World 
Health Organization (WHO) in 1988, when 
the WHO makes an attempt to standardize 
the criteria5,6.
The last harmonized definition is seventh, 
where 5 risk factors were considered as 
necessary4:
1. increased waist according to the specif-
ics of each country;
2. triglycerides ≥ 150 mg / dl,
3. HDL-C <40 mg / dl in men and <50 mg /
dl in women,
4. Systolic blood pressure ≥ 130 mm Hg
or diastolic blood pressure ≥ 85 mm Hg
and
5. Fasting glucose> 100 mg / dl.
One of the definitions is the National Cho-
lesterol Adult Tertiary Adult Tretman III 
(NCEP ATD III), a pan-III study program, 
introduced in 2001. According the defini-
tion, the definition of metabolic syndrome 
should have at least three of the following 
factors5:
1. obesity (waist circumference of 102 cm>
in men,> 88 cm in females)
2. Triglycerides ≥ 1.7 mmol / L
3. HDL-cholesterol <01.03 mmol / L in
men, <1.29 mmol / L in women
4. systolic blood pressure ≥ 130 mmHg and
/ or diastolic blood pressure ≥ 85 mmHg
5. glycemia ≥ 6.1mmol / L
In the world, the prevalence of MS ranges 
from <10% to 84%, depending on the re-
gion, urban or rural environment, the de-
mographic characteristics (sex, age, race 
and ethnicity) of the population and which 
definition of the syndrome is used (7, 8).
Aim of the study is to to determine the prev-
alence of metabolic syndrome syndrome in 
the Pech District according to NCEP ATD III 
/ 2001.
Material and methods
Cross sectional study was performed at the 
Pech‘s General Hospital, which is a region-
al hospital for the Pech district. Pech dis-
trict is one of the seven districts in Kosovo. 
The Pech district covers the municipalities 
of Pech, Klin, Dechani and Istok, accord-
ing to the latest report by UMNIK in 2011, 
the population is over 420,000 inhabitants. 
The administrative center of Pech district 
is Pech. The study included patients over 
18 years, and the exclusion criterion was 
pregnancy. Demographic data and clini-
cal parameters in this study are provided 
through a questionnaire. The WHO STEPS 
Instrument for Chronic Disease Risk Fac-
tor Surveillance  was used, adapted to the 
population in Kosovo. The questionnaire 
consisted of 5 sections, after the pilot study 
suffered minor corrections and adjusted to 
the population in the Pech district. 
Part I consists of sociodemographic data: 
sex, age, marital status, education, place of 
residence, employment, monthly income. 
Part II consists of questions for smoking 
(daily), alcohol consumption (daily con-
sumption), consumption of salt/quantity, 
fruit (frequency and quantity), spice (fre-
quency and quantity), meat, consumption 
of fat from animal or plant origin , physical 
activity during the day. Physical activity in 
42
patients according to the questionnaire re-
fers to each daily activity divided into four 
levels. Part III consists of questions about 
noticed/registered hypertension, diabetes, 
familial history of diseases (hypertension, 
heart words, diabetes). Part IV consists of 
anthropometric measurements (height, 
weight, structure between crystalline or 
the lower rib, arterial pressure measured 
in a sitting position). V part consists of 
biochemical measurements (triglycerides, 
HDL-cholestrol, LDL, glycemia).
In this paper we analyzed part IV and V of 
the questionnaire.
Kosovo uses the definition according to the 
National Cholesterol Education Program 
Adult Tretmant Panel III (NCEP ATD III).
Results
In the study, 1667 patients from Pech Dis-
trict were interview for a period of one 
year. 59.9% were from Pech, 16.6% were 
from the Istok, 13.7% were from Decani and 
9.8% were from Klin (table 1).
Table  2:   Characteristics of the interviewed patients with MS according NCEP ATD III / 
2001
Table 1:   View of the respondents by place of residence
city number %
Pech 999 59.9
Istok 276 16.6
Dechani 229 13.7
Klina 163 9.8
total 1667 100.0
conditions number %
1. triglycerides ≥ 1.7 mmol / L 479 94.7
2. systolic blood pressure ≥ 130 mmHg 503 99.4
3. diastolic blood pressure ≥ 85 mmH 488 96.4
4. HDL <1.03mmol / L - men 99 56.9
5. HDL <1.29 mmol / L - women 171 51.5
6. waist circumference> 102cm - men 114 65.5
7. waist circumference> 88cm - women 312 94.0
8. Glucose ≥ 6.1mmol / L 405 80.0
Most of the participants meet the condi-
tions set by NCEP ATD III: systolic blood 
pressure ≥ 130 mmHg -99.4%, followed 
by diastolic blood pressure ≥ 85 mmH-
96.4%, elevated triglycerides ≥ 1.7 mmol 
/ l-94.7%, waist circumference > 88cm 
in women-94.0%, elevated glycaemia ≥ 
6.1mmol / l at 80.0%, waist circumfer-
ence > 102cm in men-65.5%, HDL values 
<1.03mmol / L in men, 56.9% HDL values 
<1.03mmol / L in women 51.5% (tab 2).
According to the analysis of the data MS was registered in 506 (30.4%) of interviewed 
patients, and in 69.6% (1161) not registered according to NCEP ATD III / 2001
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Table  3:   Anthropometric and biochemical measurements in the interviewed patients with 
and without MS
height
MS average N Std.Dev. minimum maximum
with 167,3 506 6,11 147,0 190,0
without 169,4 1161 7,09 152,0 188,0
systolic BP
with 151,1 506 9,93 125,0 180,0
without 126,2 1161 9,57 111,0 160,0
diastolic BP
with 91,0 506 4,74 80,0 110,0
without 76,1 1161 6,80 60,0 95,0
weight
with 89,2 506 10,37 65,0 125,0
without 70,5 1161 8,85 50,0 99,0
waist circumference
with 103,6 506 9,29 82,0 138,0
without 84,9 1161 7,57 63,0 109,0
HDL
with 1,1 506 0,21 0,1 2,0
without 1,4 1161 0,20 0,68 2,23
LDL
with 4.0 506 1.03 1.0 10.0
without 3.2 1161 0.62 1.5 5.4
glycemia
with 6.5 506 0.58 4.4 9.0
without 4.9 1161 0.44 3.2 6.7
triglycerides
with 2,5 506 0,83 0,74 6,8
without 1,3 1161 0,26 0,59 2,8
cholesterol
with 6,2 506 1,05 3,6 13,7
without 5,2 1161 0,63 3,3 7,8
The average height in patients with MS 
is 167.3 ± 6.1 cm, and in the group with-
out MS it is 169.6 ± 7.1 cm. According to 
the Mann-Whitney U test, the difference 
is statistically significant for p <0.05 (p = 
0.000150) 
The mean value of systolic blood pressure 
in patients with MS is indicated to be 151.1 
± 9.3 mmHg, and in the group without MS 
it is 126.2 ± 9.6 mmHg. According to the 
Mann-Whitney U test, the difference is sta-
tistically significant for p <0.05 (p = 0.00). The 
average value of diastolic blood pressure in 
patients with MS is higher and amounts to 
91.0 ± 4.7 mmHg, and in the group without 
MS it is 76.1 ± 6.8 mmHg. According to the 
Mann-Whitney U test, the difference is sta-
tistically significant for p <0.05 (p = 0.00). 
The average weight in patients with MS is 
higher and amounts to 89.2 ± 0.4 kg, and 
in the group without MS it is 70.5 ± 8.9 cm. 
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Table  4:   Body Mass Index (BMI) in the interviewed patients with and without MS
According to the Mann-Whitney U test, the 
difference is statistically significant for p 
<0.05 (p = 0.000150).
 The average waist circumference of pa-
tients with MC is higher and is 103.6 ± 9.2 
cm, and in the group without MC it is 84.9 
± 7.6 cm. According to the Mann-Whitney 
U test, the difference is statistically signifi-
cant for p <0.05 (p = 0.000150).
 The mean HDL value in patients with MS 
is lower and is 1.1 ± 0.2 mmol / L, and in the 
group without MS it is 1.4 ± 0.2 mmol / L. 
According to the Mann-Whitney U test, 
the difference is statistically significant 
for p <0.05 (p = 0.00). The mean LDL value 
in patients with MS is higher and is 4.0 ± 
1.0 mmol / L, and in the group without MS 
it is 3.2 ± 0.6 mmol / L. According to the 
Mann-Whitney U test, the difference is sta-
tistically significant for p <0.05 (p = 0.00).
The average glycemic value in patients with 
MS is higher and is 6.5 ± 0.6 mmol / L (high-
er> 6.1 mmol / L than the predicted value 
with NCEP ATD III) and in the group with-
out MS it is 4.9 ± 0.4 mmol / L. According to 
the Mann-Whitney U test, the difference is 
statistically significant for p <0.05 (p = 0.00). 
The average triglyceride value in patients 
with MS is higher and is 2.5 ± 0.8 mmol / L 
(higher than> 1.7 mmol / L of the predicted 
value with NCEP ATD III), and in the group 
without MS it is 1.3 ± 0.3 mmol / L. Accord-
ing to the Mann-Whitney U test, the differ-
ence is statistically significant for p <0.05 
(p = 0.00). The average cholesterol value in 
patients with MS is higher and amounts to 
6.2 ± 1.1 mmol / L and in the MS without 
MS it is 5.2 ± 0.6 mmol / L. According to the 
Mann-Whitney U test, the difference is sta-
tistically significant for p <0.05 (p = 0.00) 
(tab 3).
Most patients with MS are obesity / obesity 
- 70.8%, overweight are 27.8%, and 1.4% nor-
mal weight (tab and graph 5), the percent-
age difference is statistically significant be-
tween versus the other modes of BMI for p 
<0.05 (Difference test, p = 0.0000)
The most common in patients without MS 
is the normal weight - 66.0%, overweight 
with 30.8%, and obesity with 3.2% (tab 4), 
the percentage difference is statistically 
significant between the normal weight ver-
sus other modalities of BMI for p <0.05 (Dif-
ference test, p = 0.0000)
The percentage difference of modalities be-
tween the two, BMI -normal weight versus 
obesity is statistically significant for p <0.05 
(Difference test, p = 0.0000), and the per-
centage difference of modalities between 
the two, BMI - overweight is statically 
non-significant for p> 0.05 (Difference test, 
p = 0.2186)
BMI    kg/m2 with MS without MS
number % number %
18,5 – 24.9 normal 7 1.4 766 66.0
25 – 29.9 overweight 141 27.8 358 30.8
>=30 obesity 358 70.8 37 3.2
total 506 100.0 1161 100.0
Discussion
The prevalence of MS is increasing paral-
lel with an increase the obesity / obesity 
epidemic. Two thirds of the population in 
America is overweight or obese, and more 
than a quarter of the population meets the 
criteria for MS. For 20 years, the survey in 
America has seen an increase in the preva-
lence of 27% (1988/94) to 32% (1999/00)1-10. 
According to world calculations, four out 
of five deaths were MS consequences will 
occur in countries with low and middle in-
come. In Europe and North America there 
are gradual changes in lifestyle over the 
centuries, where diet based on high car-
bohydrate intake is replaced by high pro-
tein intake. Similar changes occur in third 
world countries, but in many cases the 
transition takes place over decades. The 
combination of increased access to food, 
reduced physical activity leads to increased 
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prevalence of obesity, dyslipidaemia, hyper-
tension, and hyperglycaemia / diabetes, the 
combination of which is called a metabolic 
syndrome1-10.
Metabolic syndrome is a public health glob-
al problem. About a quarter of the Europe-
an adult population is estimated to have 
metabolic syndrome, with similar preva-
lence being registered in Latin America10. 
It represents a new epidemic in the devel-
opment of East Asian countries, includ-
ing China, Japan and Korea. In Japan, the 
Ministry of Health, Labor and Social Affairs 
introduced a screening and intervening 
program11. The metabolic syndrome was 
recognized as very common problems in 
many other countries in the world12-17.
The results of the study show a high prev-
alence of MS in the Pech District in 30.4% 
of the interviewed patients. Systolic blood 
pressure was ≥ 130mmHg in 99.4% of partic-
ipants, followed by diastolic blood pressure 
≥ 85mmHg in 96.4%, elevated triglycerides 
≥ 1.7 mmol/l in 94.7%, waist > 88cm in wom-
en 94.0% , elevated glycose ≥ 6.1mmol/L in 
80.0%, waist > 102cm in men-65.5%, de-
creased HDL<1.03mmol/L in men-56.9% 
and HDL values <1.29mmol/L in females 
51.5% . Such a prevalence of factors that de-
termine MS can lead to an increase the rate 
of cardiovascular disease and diabetes.
Similar conclusions come from the study 
prepared in 2012 in the Tetovo region 
where the prevalence of MS is 28.25% and 
there was a high prevalence of arterial 
hypertension, hypertriglyceridemia and 
visceral adipositis. The rate of elevated 
triglyceride levels was 39.05%, decreased 
levels of HDL-C 46.35%, visceral adipositus 
up 43.17%, increased glucose up to 25.24%, 
and increased arterial pressure at 52.06%. 
The limit value in the study of hyperglycae-
mia is 5.6 mmol/L, and in our study it was 
6.1 mmo /L. The study shows a high prev-
alence of metabolic syndrome by sex, age 
and ethnicity, as well as related socio-eco-
nomic and behavioral indicators, such as 
education levels, family income levels, and 
degree of physical activity18.
In a study performed in Greece in 9696 
people, the overall prevalence according 
to the definition of NCEP-ATP III was lower 
-24.5%19. Lower prevalence was registered 
in Bulgaria in 575 healthy people -23%20.
The study performed in Romania, with 
2200 participants, has shown that prev-
alence was 24%. A larger prevalence was 
registered in Croatia 34% 21,22.  A higher 
prevalence of MS was recorded in the Unit-
ed States of the general population of 34% 
in the NHANES study 2003-2006 (National 
Health and Examination Survey Nutrition), 
the 1988-1994 prevalence according to the 
criteria ATPIII was 29,20%23.
The Korean epidemiological study “Korean 
National Health and Nutrition Examina-
tion Survery” for the period 1998-2007, has 
shown continuous increase of the preva-
lence, in 1998 it was 24.9%, in 2001-29.2%, 
in 2005-30.4%, and in 2007 - 31.3% 24.
In some Western European countries, a 
stagnation of prevalence has been regis-
tered in recent years as a result of measures 
taken to reduce risk factors such as in the 
MONA LISA study in France, it was made 
comparison between 3405 respondents in 
1996 and 3554 respondents in 200625. 
Kaur et al. 26 reported that worldwide the 
prevalence of the Metabolic Syndrome (MS) 
was between 10 and 84% depending on eth-
nicity, age, gender, and race, while IDF es-
timates that a quarter of the world’s popu-
lation has MS. According to Pal and Ellis27 , 
20% of adults in the Western world had MS.
From 2003 to 2012, the overall prevalence 
of metabolic syndrome in the United States 
was 33% (95% CI, 32.5% -33.5%) 28.
A study in Turkey found that the preva-
lence of metabolic syndrome was 34.6% 29. 
Tan et al. showed that 96.1%, 95.8%, 84.8% 
and 97.7% of 313 diabetic patients aged ≥30 
years had metabolic syndrome, using the 
definition of NCEP, ATPIII, IDF and harmo-
nized definition30.
According to the study of Beltrán-Sánchez 
and colleagues31, the MS was a combination 
of health disorders such as obesity, high 
blood pressure, type 2 diabetes, decreased 
lipids, contributing to cardiovascular dis-
ease and death.
Conclusions
The prevalence of MS in the Pech district 
was 30.4% and was approximately as in 
Croatia 34% and Tetovo region with 28.25%, 
but it is dependent on the population and 
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definitions used.
The prevalence of systolic blood pressure 
≥ 130 mmHg is 99.4% and the prevalence 
of diastolic blood pressure ≥ 85 mmH was 
96.4%. Prevalence of elevated triglycerides 
≥ 1.7 mmol/L was 94.7%.The prevalence of 
waist > 88cm in women was 94.0% and waist 
> 102cm in men was 65.5%. Prevalence of 
increased glucose ≥ 6.1mmol/L  was 80.0%. 
Prevalence of reduced HDL <1.03mmol/L in 
men -56.9% and HDL values <1.29 mmol / L 
in women 51.5%
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